Trade Ideas
U.S. senators are set to introduce bipartisan legislation to ban sports bets on prediction markets like Kalshi and PolyMarket, which have been seen as competitive threats to DraftKings and Flutter. Reduced competition from these emerging prediction market platforms could ease pressure on traditional sports betting operators. Both stocks rose on the news (DKNG +1%, Flutter +4.4%), indicating a positive market read on the potential regulatory change. The legislation may not pass or may be diluted; competitive dynamics could shift again.
Cruise lines were top gainers in the S&P, with Carnival and Royal Caribbean up over 5%, following President Trump backing off threats regarding Iran. Geopolitical de-escalation reduces perceived risk for the travel and leisure sector, driving investor optimism. The stocks' significant gains reflect a swift reassessment of risk premia attached to travel companies. The situation remains fluid; further geopolitical escalation could immediately reverse the gains.
Palantir's Maven Artificial Intelligence system will reportedly become an official program of record for the Pentagon, central to its AI-enabled combat operations strategy. This formalizes a major defense contract, validating Palantir's AI technology and securing a significant government revenue stream. The stock rose ~6.8% and topped the Nasdaq 100, demonstrating strong market approval of this business milestone. Government program timelines and budgets are subject to change and political oversight.
Micron shares fell 4.4%, continuing a decline after the company reported capital expenditure for the year that was higher than analysts expected. Higher CapEx raises concerns about near-term profitability, free cash flow, and return on investment in a cyclical industry. The stock's persistent drop (-13.5% from recent highs) shows investor disappointment and a reassessment of earnings prospects. The increased spending could lead to greater market share or production efficiency longer-term.
Pfizer's experimental Lyme disease vaccine was only 73% effective in a pivotal study, a lackluster result complicated by fewer-than-expected infections. The suboptimal efficacy data and challenging study dynamics could delay regulatory approval or limit the vaccine's commercial potential in an untapped market. The stock underperformed in a strong market, down 0.7%, reflecting diminished expectations for this product. Further analysis of the data or adjustments to the trial could improve the outlook.
FICO shares fell 5.7% after Politico reported Senator Josh Hawley queried the company over its mortgage credit scoring price increases, which he stated burden first-time homebuyers. Political and regulatory scrutiny creates uncertainty around FICO's pricing power and could pressure future profitability. The sharp decline indicates investor concern about the material risk of regulatory intervention in its core business. The inquiry may not lead to concrete action or legislation.
Estee Lauder shares dropped 7.7% late in the session on reports it is nearing a deal to combine with Spanish beauty firm Puig Brands. The market is interpreting the potential transaction as value-destructive, likely due to concerns over the price, strategic fit, or dilution. The severe negative reaction suggests investors disapprove of the deal's perceived terms or strategic merit. The final deal terms may be more favorable than initially reported, or the transaction could unlock strategic value.
This Bloomberg Markets video, published March 23, 2026,
features Katie Greifeld
discussing DKNG, FLUTTER, CCL, RCL, PLTR, MU, PFE, FICO, EL.
7 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Katie Greifeld
· Tickers:
DKNG,
FLUTTER,
CCL,
RCL,
PLTR,
MU,
PFE,
FICO,
EL